Issue 29, 2025, Issue in Progress

Exploring the potential molecular targets and therapeutic mechanisms of Cyperi Rhizoma in treating diabetic cardiomyopathy: a computational approach

Abstract

Diabetic cardiomyopathy (DCM) is a major contributor to heart failure in diabetic patients, characterized by complex pathophysiological mechanisms and a lack of effective targeted therapies. Cyperi Rhizoma (CR), a traditional Chinese medicinal herb, has shown potential in regulating Qi and improving metabolic disorders, yet its therapeutic mechanisms in DCM remain unclear. This study systematically explored the bioactive components and underlying mechanisms of CR in the treatment of DCM by integrating network pharmacology, molecular docking, molecular dynamics simulation (MDS), and in vitro experiments. Active compounds of CR were identified, and DCM-related targets were obtained from GEO, DisGeNET, OMIM, and GeneCards databases. Quercetin, luteolin, and patchoulenone were identified as key compounds, while AKT1, IL6, TNF, IL1B, and TP53 emerged as core targets. Functional enrichment analysis indicated that the AGE-RAGE and TNF signaling pathways may play critical roles in the protective effects of CR against DCM. Molecular docking and MDS demonstrated a stable binding interaction between luteolin and AKT1. Furthermore, in vitro validation confirmed the protective effect of luteolin against high glucose and palmitic acid-induced injury in H9c2 cardiomyocytes. Collectively, this study elucidates the multi-level pharmacological basis and molecular mechanisms of CR in mitigating DCM, providing a theoretical and experimental foundation for its potential therapeutic application.

Graphical abstract: Exploring the potential molecular targets and therapeutic mechanisms of Cyperi Rhizoma in treating diabetic cardiomyopathy: a computational approach

Supplementary files

Article information

Article type
Paper
Submitted
10 Apr 2025
Accepted
01 Jul 2025
First published
08 Jul 2025
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2025,15, 23920-23933

Exploring the potential molecular targets and therapeutic mechanisms of Cyperi Rhizoma in treating diabetic cardiomyopathy: a computational approach

S. Lu, Z. Fu, Y. Xia, Y. Xu, F. Wang, Z. Pan, Y. Tu, W. Peng, M. Han, W. Yu and W. Zha, RSC Adv., 2025, 15, 23920 DOI: 10.1039/D5RA02505B

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements